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Human brain tumors appear to have a hierarchical
cellular organization suggestive of a stem cell foun-
dation. In vitro expansion of the putative cancer
stem cells as stable cell lines would provide a power-
ful model system to study their biology. Here, we
demonstrate routine and efficient derivation of
adherent cell lines frommalignant glioma that display
stem cell properties and initiate high-grade gliomas
following xenotransplantation. Significantly, glioma
neural stem (GNS) cell lines from different tumors
exhibit divergent gene expression signatures and
differentiation behavior that correlate with specific
neural progenitor subtypes. The diversity of gliomas
may, therefore, reflect distinct cancer stem cell
phenotypes. The purity and stability of adherent GNS
cell lines offer significant advantages compared to
‘‘sphere’’ cultures, enabling refined studies of cancer
stem cell behavior. A proof-of-principle live cell
imaging-based chemical screen (450 FDA-approved
drugs) identifies both differential sensitivities of GNS
cells and a common susceptibility to perturbation of
serotonin signaling.
INTRODUCTION
The most common and aggressive type of primary adult brain
cancer is malignant glioma. Current treatments for these cancers
are largely ineffective. Gliomas are classified as astrocytoma, oli-
godendroglioma, or ependymoma, based on the glial cell type
that predominates in the tumor (Kleihues and Cavenee, 2000).
Glioblastoma multiform (GBM) is the most common and aggres-
sive form of malignant astrocytoma and can arise de novo or568 Cell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc.from pre-existing lower-grade tumors (Kleihues and Cavenee,
2000). Molecular profiling of GBM tumors has suggested distinct
subclasses of the disease (Mischel et al., 2003; Louis, 2006; Phil-
lips et al., 2006). However, individual tumors contain varying
proportions of apparently differentiated cell types, alongside ill-
defined anaplastic cells, which complicates accurate diagnosis
and grading. Though there has been success in identifying the
disrupted signaling pathways and underlying genetic defects
associated with glial tumors (Furnari et al., 2007; Cancer
Genome Atlas Research Network, 2008), it remains unclear
how these operate in different cellular contexts.
It is possible that cellular heterogeneity within each tumor
arises from cells that display stem cell characteristics—namely,
long-term self-renewal and capacity to differentiate, as previ-
ously demonstrated for leukemia (Lapidot et al., 1994). Such
stem cells would underlie a cellular hierarchy and drive tumor
growth through sustained self-renewal. We, and others, have
shown that a subpopulation of putative cancer stem cells can
be isolated from diverse adult and childhood brain tumors using
the neural stem cell marker CD133 (Hemmati et al., 2003; Singh
et al., 2003), and these can initiate tumor formation following
xenotransplantation (Singh et al., 2004). These data, together
with similar approaches for other solid tumors, provide support
for the cancer stem cell hypothesis (Reya et al., 2001; Ward
and Dirks, 2007).
Establishing cell lines from tumors that retain cancer-initiating
stem cell properties would provide a valuable and accurate
model of the human disease. It would also give insight into the
origin of tumor heterogeneity and enable more refined analysis
of molecular mechanisms that regulate transformation, self-
renewal, commitment, and differentiation. Together with comple-
mentary studies using mouse genetic models, these approaches
should lead to more rational therapeutic strategies. The neuro-
sphere culture paradigm has been used successfully for enrich-
ment of tumor-initiating cells from brain tumors (Ignatova et al.,
2002; Hemmati et al., 2003; Singh et al., 2003; Galli et al., 2004;
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GBM has, in some cases, been possible in serum-free media,
and such cultures are an improvement on ‘‘classic’’ glioma cell
lines, such as U87, or other serum-cultured lines, which fail to
model accurately the human disease (Galli et al., 2004; Lee
et al., 2006). However, neurosphere culture has several limita-
tions. Short-lived progenitor cells also proliferate in suspension
culture, and true clonal analysis is hampered by sphere aggrega-
tion (Suslov et al., 2002; Reynolds and Rietze, 2005; Singec et al.,
2006). Most problematic is the spontaneous differentiation and
cell death that accompany stem cell divisions in the sphere envi-
ronment. This limits rigorous assessment of stem cell behavior
and marker analysis based on bulk populations (Suslov et al.,
2002). Thus, the true nature of the stem cell compartment across
the spectrum of gliomas and their relationship to in vivo progen-
itors remain unclear (Stiles and Rowitch, 2008).
We recently reported methodology for deriving and expanding
mouse and human adherent neural stem (NS) cell lines (Conti
et al., 2005; Pollard et al., 2006; Sun et al., 2008). Adherent
culture provides uniform access to growth factors, which
suppresses differentiation and enables expansion of highly
pure populations of stem cells. In this study, we investigated
whether gliomas may yield glioma neural stem (GNS) cell lines
in similar adherent culture conditions.
RESULTS
Adherent NS-like Cell Lines Can Be Established Readily
from Human Gliomas
The key requirement for propagating both mouse and human NS
cells without spontaneous differentiation or cell death is a combi-
nation of the growth factors EGF and FGF-2 on an adherent
substrate (Conti et al., 2005; Sun et al., 2008). We tested whether
these conditions enable the isolation and expansion of stem cells
from gliomas. Glioma tissue was recovered following surgical
procedures and was immediately processed (see Supplemental
Experimental Procedures available online). Following direct
plating onto a laminin-coated flask in NS cell culture media, we
observed survival and establishment of primary cultures from
all glioblastoma samples tested (Figure 1A). There is a diversity
of cellular phenotypes within these initial cultures, reflecting
mixtures of progenitors and differentiated cells together with
putative stem cells.
For some samples, high levels of cell death within the tumor
mass interfered with establishment of adherent cultures due to
excessive cell debris binding to the substrate. In these instances,
cells initially formed aggregates, or neurospheres. After 7–10
days, these were harvested free from dead cells and debris
and allowed to settle and attach. NS cells grow out from these
primary spheres (Figure 1A), as previously demonstrated for
mouse and human NS cells (Conti et al., 2005; Sun et al.,
2008). Using each of these derivation approaches, we are
routinely able to generate adherent primary cultures of human
malignant glioma cells.
Cultures expanded continuously with a doubling time of
around 3–5 days. Within 2–3 passages, cultures became less
heterogeneous. As for fetal NS cells, we find that a laminin
substrate provides the most effective means to propagate the
cells, while parallel cultures on gelatin or untreated plasticundergo cell clumping, and cells detach (data not shown). Using
these adherent conditions, we have been able to expand six cell
lines for at least 1 year (>20 passages) without any obvious crisis
or alteration in growth rate, although genetic alterations did
occur at late passage (see below). Cell lines were established
from histopathologically distinct types of tumor, namely three
cases of glioblastoma multiforme (G144, G166, and GliNS2),
a giant cell glioblastoma (G179), and an anaplastic oligoastrocy-
toma (G174). For one glioma sample (patient no. 144), we estab-
lished cell lines independently in each of our laboratories using
the same initial tumor sample. These cell lines were designated
G144 and G144ED. In all subsequent analyses performed, we
have found no striking differences in behavior or marker expres-
sion between these two cell lines.
To ascertain whether the glioma-derived cells have similarities
to fetal NS cells (Sun et al., 2008), we undertook a phenotypic
characterization of NS cell/neural progenitor cell markers. Immu-
nocytochemistry confirmed that nearly all cells within the culture
express Vimentin, Sox2, Nestin, CD44, and 3CB2, although for
each of these, there appears to be some variations in levels
between cells (Figure 1B and data not shown). By time-lapse vid-
eomicroscopy, it is apparent that cells within G144 and G179
cultures display dynamic changes in cell shape and are highly
motile, both features of fetal NS cells (Movies S7 and S11). Quan-
titative data generated from cell tracking analysis identified that
G166 cells are less motile than G144 cells, with the later moving
on average 1.8 times further from their initial position (Movies S1–
S4). Thus, glioma-derived cell lines are broadly similar to normal
NS cells. Therefore, we term them glioma NS (GNS) cells. Each
line can be efficiently recovered following freezing and thawing
and can readily be genetically modified using nucleofection
(see Supplemental Data).
To compare the efficiency with which adherent GNS cell lines
can be established compared to suspension culture (sphere)
methods, we performed side-by-side derivation for an additional
six primary tumor samples (five GBMs and one anaplastic oligo-
dendroglioma). The primary glioma cell population was split into
two flasks, one coated with laminin and the other without (sphere
conditions). Strikingly, using the adherent NS cell conditions, we
were able to establish cultures from all six samples, and these
were all expanded for at least 10 passages. By contrast, in
suspension culture, although most samples generated
spheres/aggregates upon initial plating, only two of these could
be passaged further. For these two sphere cultures, we noted
reduced expansion compared to side-by-side adherent cultures
(passage 5 for each glioma sphere culture versus > passage 10
for all six adherent GNS cells).
Increased efficiency of establishing and propagating glioma
cells in adherent conditions may be attributable to increased
differentiation and apoptosis in sphere culture. This is analogous
to the embryonic stem cell cultures that are maintained as pure
stem cell cultures in adherent culture but undergo differentiation
when plated in suspension, generating embryoid bodies
(Doetschman et al., 1985). We compared the extent of differen-
tiation and apoptosis in side-by-side cultures expanded either
adherently or as spheres (Figure 2). This analysis was performed
using established adherent lines to generate spheres (G144,
G144-D6, and G179). As the initial starting cell population is
the same, this experiment compares directly the effects of theCell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc. 569
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Glioma NS Cell LinesFigure 1. Derivation and Initial Characterization of GNS Cells
(A) Typical example of primary cultures established by plating of glioma tumor populations directly on a laminin substrate in NS cell expansion media (left) or briefly
maintained in suspension and then plated in a laminin-coated flask (right).
(B) Immunostaining for the neural progenitor markers Nestin, Sox2, Vimentin, and CD44 in three different glioma cell lines (G144, G166, and G179) and one fetal
NS cell line (CB541).570 Cell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc.
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Adherent GNS cells (the clonal line G144-D6) readily generated spheres when
plated in suspension culture (A). After two passages in identical medium with
EGF and FGF-2, immunocytochemistry was performed to assess differentia-
tion to oligodendrocytes (B) or TuJ-1+ neurons and GFAP-expressing astro-two culture regimes. Handling of cells, dissociation, staining, and
media used were carried out in parallel. We found increased
numbers of cells expressing differentiation markers in the
spheres (GFAP, O4, and TuJ-1) (Figures 2B and 2C), as well as
increased levels of cell death using the TUNEL assay and An-
nexin V staining (36% versus 15%) (Figures 2D and 2E). We
also examined the cultures maintained continuously as spheres
and their adherent counterparts and similarly found higher levels
of differentiation markers in the spheres (Figure S1). Together,
these findings indicate that monolayer culture enables routine
expansion of glioma cells with reduced levels of differentiation
and apoptosis. Three cell lines (G144, G166, and G179) are
characterized in detail in this study.
Genomic Aberrations in GNS Cells
To determine whether GNS cells display genomic alterations
characteristic of GBM, we performed molecular cytogenetic
analyses using spectral karyotyping (SKY), locus-specific
FISH, and comparative genomic hybridization (Figures S2 and
S3). G144 cultures exhibited no aberrant chromosomes and
contained a mixture of diploid (2n) and tetraploid (4n) cells.
Simple numerical gains of chromosomes 7 and 19, together
with loss of chromosomes 6, 8, and 15, were identified. With
the exception of chromosome 8 deletion, each of these changes
is commonly associated with glioblastoma (Cancer Genome
Atlas Research Network, 2008; Parsons et al., 2008). Increased
copy numbers of chromosome 7 were confirmed by EGFR-
specific interphase FISH using tissue samples derived from the
surgical resection of the tumor, as well as cultured cells
(Figure S2). It is noteworthy that the EGFR, CDK6, and MET
genes map to this chromosome. Comparative genomic hybrid-
ization for G144 revealed an amplification of the CDK4 locus
on chromosome 12 and deletion of PTEN on chromosome 10.
Two clonal cell lines generated from the G144 population
(expanded for more than 6 months) exhibited no major change
from the parental population (Figure S3). However, late passage
G144 (passage 50) cultures did show a more complex and
heterogeneous pattern of both numerical and structural chromo-
somal change (Figure S2). Similarly, G179 exhibited a more
complex chromosomal constitution at later passages, and
similar to G144, polysomic gain of whole chromosome 7 was
evident. Thus, although GNS cells do not display gross chromo-
some instability, alterations in whole chromosome copy number
do occur following long-term in vitro expansion. Therefore, we
routinely use cultures expanded for no more than 20 passages.
GNS Cell Lines Are Tumorigenic
To test the capacity of GNS cells to initiate tumor formation, we
carried out intracranial transplantation into immunocompro-
mised mice. Initially, we injected 100,000 cells from G144
cultures (expanded > 10 passages). After 5 weeks, a first cohort
of mice was sacrificed and revealed large numbers of engrafted
human nestin immunoreactive cells that had infiltrated the host
brain (Figure S4). A second cohort of mice was sacrificed after
cytes (C). Cell death is higher within spheres than within adherent cultures,
as determined by TUNEL (D) and Annexin V staining (E). Similar results were
obtained for G144 and G179.Cell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc. 571
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large and highly vascularized tumors (Figure 3A).
The histopathology of these xenograft tumors is strikingly
similar to human GBM tumors, namely pseudopalisading
Figure 3. G144 Cells Generate Tumors following Xenotransplan-
tation
(A) GNS cells that were transplanted into immunocompromised mice
produced a large tumor mass (22 weeks after transplantation of 105 G144
cells, passage 18).
(B) A similar xenograft tumor sectioned and assessed for histopathology dis-
played hallmarks of GBM. HE, hematoxylin and eosin.
(C) Flow cytometry quantitation of CD133+ cells within the directly harvested/
uncultured xenograft compared to the original patient tumor.
(D) Immunocytochemistry for Nestin (red) and GFAP (green) in xenograft
tumors.
(E) The original G144 patient tumor was graded as GBM. However, consistent
with the G144 in vitro differentiation, CNPase+ oligodendrocyte-like cells are
widespread (F).
(G) Kaplan Meier plots for transplants of G144 cells exposed to each differen-
tiation condition for 14 days prior to transplantation of 200,000 cells (n = 6
for condition).572 Cell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc.necrosis, nuclear pleomorphism, and extensive microvascular
proliferation (Kleihues and Cavenee, 2000) (Figures 3A and 3B).
Cellular heterogeneity is evident within the xenograft tumor pop-
ulation upon immunostaining for Nestin and GFAP or flow cytom-
etry for CD133 (Figures 3C and 3D). CD44 and Nestin-expressing
tumor cells are frequently identified on the periphery of the
tumors, with GFAP more prominent centrally, suggesting that
the most primitive cells are invasive (Figure S5). Transplantation
of G144 cells after exposure to differentiation-promoting condi-
tions in vitro resulted in delayed tumor formation (Figure 3G).
G166 and G179, as well as two other GNS cell lines tested
(G174 and GliNS2), also generated tumors (Figure 4A and Table
S1). Highly infiltrative behavior characterizes high-grade glioma
and makes full surgical resection of the tumor population impos-
sible. In most transplants, we saw a striking infiltration of the
brain reminiscent of the human disease. An exception was
G166, which generated a more defined tumor mass (Figure 4A).
To calibrate tumor-initiating potency, we carried out trans-
plantations using 10-fold dilutions of cells (n = 47). The minimum
number of cells tested (100) resulted, in most cases, in cell
engraftment and for two lines (G144 and G174) was sufficient
to generate an aggressive tumor mass (Table S1). This is consis-
tent with our previous findings with acutely isolated CD133+ cells
(Singh et al., 2004). G166 and G179 generated tumors using
1000 cells. Clonal expansion from a single G144 cell in vitro fol-
lowed by transplantation also resulted in similar tumors
(Figure S5). These results contrast sharply with normal fetal NS
cells, which never generated tumors even using 105 cells (n = 5)
(Figure 4A). To determine whether the tumor-initiating cells self-
renew within the xenograft, we carried out serial transplantations
from the tumor mass into secondary and tertiary recipients using
G144 cells. In each case, tumors were generated (Figure 4B). Re-
derivation of long-term expandable GNS cells from G144-ED
and G179 xenograft tumors was also straightforward using
adherent conditions. However, parallel cultures expanded using
suspension culture methods failed to expand past passages
5 and 6, respectively. Together, these data demonstrate that
long-term expanded glioma-derived stem cell lines remain highly
tumorigenic and are capable of forming tumors that appear to
recapitulate the human disease.
GNSCell LinesExhibit DistinctDifferentiation Behaviors
In Vitro
A defining property of stem cells is their ability to generate differ-
entiated progeny. The most prevalent form of glioma is referred
to as astrocytoma, based on the predominance of GFAP+ astro-
cyte-like cells within the tumor mass. However, GBMs also
contain anaplastic cell populations and, in some cases, an oligo-
dendrocyte component (Kleihues and Cavenee, 2000).
For all GNS cells analyzed and in contrast to glioma neuro-
spheres (Yuan et al., 2004), we find that differentiation to oligoden-
drocytes (O4+) or neurons (TuJ-1+) is fully suppressed in the pres-
ence of EGF and FGF-2 (Figure 5A). We tested the capacity of
GNS cells to undergo oligodendrocyte or neuronal differentiation
upon growth factor withdrawal. In contrast to fetal NS cells, G144
and G179 GNS cells did not undergo massive cell death in
response togrowth factor withdrawal but, instead,began to differ-
entiate (Movies S5–S12). For G144, we noted the appearance of
significant numbers of O4+ or CNPase+ oligodendrocyte-like cells
Cell Stem Cell
Glioma NS Cell Lineswithin 1 week (Figure 5B and data not shown). By contrast, G179
mainly produced TuJ-1+ cells (Figure 5B). Neuronal-like cells or
oligodendrocytes were not apparent in G166 cultures, which
continued to proliferate in the absence of EGF and FGF-2 without
overt differentiation (Figure 5 and Movie S10).
To determine whether GNS cells could generate astrocytes,
we exposed cells to BMP-4 or serum. For G144 and G179, within
Figure 4. All GNS Cell Lines are Tumori-
genic
(A) Xenotransplantation of each GNS cell line led to
formation of a tumor mass with highly infiltrative
behavior (arrow), except for G166. (Left) Coronal
section of brain stained with H&E. (Right) Staining
for human nestin (boxed region of middle panels).
Foetal NS cells (hf240) fail to generate tumors.
(B) G144 xenograft-derived cells serially trans-
planted into secondary and tertiary hosts.
7 days following addition of BMP-4,
we observed a striking change in cell
morphology. The majority of cells ex-
pressed high levels of GFAP, although in
each case, there was also a minor popu-
lation of Doublecortin+ (Dcx+) neuronal-
like cells (Figure 5C). This response is
similar to that of human fetal NS cells
(Sun et al., 2008). Similar results were
seen upon serum treatment (data not
shown). For G166, GFAP+ cells were
also observed, but only at low frequency.
Thus, whereas GNS cells retain a capacity
to differentiate, efficiency and lineage
choice vary dramatically between each
line.
GNS Cell Lines Have Properties
Related to Specific Classes
of Neural Progenitors
The tendency of G144 cells to differen-
tiate into oligodendrocytes was sur-
prising. For mouse and human fetal NS
cells, efficient oligodendrocyte differenti-
ation requires a stepwise differentiation
protocol involving exposure to the exoge-
nous signals, thyroid hormone, ascorbic
acid, and PDGF and results in heteroge-
neous populations of neurons, astro-
cytes, and oligodendrocytes (Glaser
et al., 2007; Sun et al., 2008). G144 cells
may represent a corrupted tripotent state
that has acquired genetic changes that
influence the lineage choice during differ-
entiation, biasing toward oligodendro-
cyte commitment. Alternatively, G144
cells may have a distinct phenotype
more similar to oligodendrocyte pre-
cursor cells (OLPs) than to NS cells. To
distinguish between these two possibili-
ties, we assessed established markers of OLPs (Olig2, Sox10,
NG2, and PDGFRa) to identify whether they are expressed prior
to or during differentiation.
Using immunocytochemistry, we find that G144 cells, but not
G166, G179, or human fetal NS cells, coexpress Sox10 and NG2
in proliferating conditions (Figure 6A). Quantitative RT-PCR
confirmed that G144 cells express higher levels (>50-fold) ofCell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc. 573
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Glioma NS Cell LinesFigure 5. GNS Cell Lines Exhibit Distinct Differentiation Behavior
(A) In proliferating conditions (EGF and FGF-2), there is no detectable differentiation of G144, G166, or G179 cells into oligodendrocytes (green, O4+) or neuron
(red, TuJ-1+).
(B) Seven days of growth factor withdrawal resulted in oligodendrocyte differentiation for G144 cultures, and G179 produced TuJ-1+ neurons.
(C) Following exposure to BMP-4 for 1 week, both G144 and G179 efficiently differentiate into GFAP+ cells, together with a minor population of Dcx+ neurona
precursors. (‘‘Live,’’ phase-contrast image of live cultures).Olig2, PDGFRa, and PDGFA than do other GNS cell lines and
fetal NS cells. To verify that the observed marker heterogeneity
was intrinsic to the GNS cells and not due to mixed populations,
we generated clonal cell lines by single-cell deposition and as-
sessed marker expression. For each line (n = 3), we saw hetero-
geneous expression of Olig2, Sox10, and NG2, similar to the
parental line, and a capacity to generate oligodendrocytes
upon growth factor withdrawal (Figure S6). G144 cells, therefore,
stably exhibit an oligodendrocyte precursor-like phenotype prior
to initiation of differentiation by growth factor withdrawal.
Consistent with the oligodendrocyte differentiation in vitro, histo-
pathological examination of sections from G144 xenograft
tumors, including those generated from G144 clonal lines, iden-
tified cells with the typical ‘‘fried-egg’’ appearance indicative
of an oligodendrocyte component (Figure S5). Furthermore,
although diagnosed as a malignant astrocytoma (GBM), re-
examination of the original patient tumor for G144 revealed
a significant oligodendrocyte component based on histopa-
thology and CNPase staining (Figures 3E and 3F).
GFAP is expressed in radial progenitors/radial glia in the
developing primate nervous system, as well as in putative neural
stem cells within the adult subventricular/subependymal zone
(SVZ) (Levitt and Rakic, 1980; Doetsch et al., 1999). Human fetal
NS cell lines express low levels of GFAP (Conti et al., 2005; Sun
et al., 2008). Following BMP treatment, G179 cells upregulated
GFAP (Figure 5C). However, prior to treatment, G179 cells
express detectable levels of GFAP, in contrast to G144 cells,574 Cell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc.which are predominantly negative. We assessed levels of an
alternative splice form of GFAP, termed GFAPd, which has
been shown to mark human SVZ astrocytes (Roelofs et al.,
2005). Expression of GFAPd mRNA was greater than five times
higher in G179 than in G144 and G166 (Figure 6B). Immunoblot-
ting confirmed increased levels of protein (Figure 6C), and immu-
nocytochemistry showed polymerized filaments of GFAPd
(Figure 6A). We find perinuclear enrichment of GFAPd filaments
similar to the staining reported for SVZ astrocytes in vivo (Roelofs
et al., 2005). Levels of GFAPd decrease following in vitro differen-
tiation (Figure S7). We also identified GFAPd-expressing cells
within the original G179 patient tumor. These did not colocalize
with CNPase-positive cells (Figure 6D). The coexpression of
GFAPd, Sox2, and Nestin and the ability to generate neuronal-
like cells in vitro are features conserved with adult SVZ astro-
cytes (Sanai et al., 2004).
G166 cells lack expression of GFAPd and OLP markers but do
express CD44 and differentiate toward GFAP+ astrocytes
in vitro, suggesting a similarity to a more restricted astrocyte
precursor. Together, these findings suggest that, despite their
shared capacity to proliferate in response to EGF and FGF-2
and the widespread expression of neural progenitor markers,
there are underlying differences between GNS cell lines. This
may reflect relatedness to distinct subtypes of ‘‘normal’’ neural
progenitor. These data further suggest that GFAPd may be of
use in discriminating astrocyte-like cells that have stem cell
properties.
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To evaluate the relationship between each GNS cell line and their
correspondence to fetal NS cells, we carried out global mRNA
expression profiling using microarrays. Principal component
analysis reveals that each GNS cell line has a transcriptional
Figure 6. GNS Cells Express Lineage-
Specific Characteristics
(A) Immunostaining in proliferating conditions
identifies differential expression of lineage
markers.
(B) Quantitative RT-PCR analysis. Control (hES) is
a human embryonic stem cell line (hED1).
(C) Immunoblot for the adult SVZ astrocyte marker
GFAPd.
(D) GFAPd-expressing cells in the original G179
patient tumor. The original G144 patient tumor
contains large numbers of CNPase cells and cells
with lower levels of GFAPd.
(E) Principal component analysis (PCA) of global
mRNA expression in each GNS cell line (black,
G144, G144ED, G166, G179, G174, and GliNS2),
fetal NS cells (red, hf240, hf286, and hf289), and
normal adult brain tissue (blue). The ‘‘a’’ and ‘‘b’’
signify biological replicates.
state more closely related to fetal NS cells
than to adult brain tissue (Figure 6E).
Consistent with the previous analysis,
we find that G179 and G166 have
a distinct expression profile, both from
one another and to G174, G144, and
GliNS2.
We performed a cluster analysis using
known NS cell and lineage-specific
markers, as well as pathways known to
be disrupted in gliomas (Figure S8). The
dendrogram generated is similar to that
for the global PCA analysis, indicating
that this set of markers is sufficient to
distinguish between lines. These data
also confirmed that G144 expresses the
OLP cell markers Sox8, Sox10, Olig1,
Olig2, and Nkx2.2, whereas these are
expressed at lower levels in G179, which
has higher levels of GFAPd. GliNS2
clusters closely with G144 and also
expresses the OLP cell markers, sug-
gesting that the phenotype of G144 may
not be unique (Figure S8). Indeed,
using immunostaining, we confirmed
that GliNS2 expresses NG2, Olig2, and
Sox10 and can generate oligodendro-
cytes readily upon growth factor with-
drawal (Figure S9). G174 (derived from
an oligoastrocytoma) did cluster closely
to GliNS2 and G144, expressing higher
levels of Olig2 and NG2. However, we
failed to detect Sox10 protein by
immunocytochemistry or oligodendro-
cyte differentiation (Figure S9). We found no evidence for expres-
sion of the pluripotency markers Oct4 or Nanog in any of the
samples.
G166 shows higher levels of EGFR than any other line, perhaps
explaining its resistance to differentiation upon EGF withdrawalCell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc. 575
Cell Stem Cell
Glioma NS Cell Linesor BMP treatment. We also noted an apparent lack of mRNA for
prominin-1 (CD133). Using flow cytometry, we examined the
status of the cell surface markers CD133 and CD15/SSEA-1,
which mark fetal and adult neural progenitors (Uchida et al.,
2000; Capela and Temple, 2002) and also brain tumor-initiating
cells (Singh et al., 2004). For G144 and G179, we observe hetero-
geneity for both markers within GNS cell cultures, similar to fetal
NS cells (Sun et al., 2009), whereas G166 is negative, consistent
with microarray expression data (Figure S10). We also found no
evidence for CD133 expression within the original G166 tumor
sample (data not shown). Lack of CD133 expression in certain
glioma cell lines has also recently been described by Beier
et al. (2007). By contrast, we find that, for each GNS cell line,
including G166, the hyaluronic acid-binding protein CD44 is
uniformly expressed. CD44 has previously been characterized
as an astrocyte precursor marker, but we recently demonstrated
that it also marks NS cells in vitro (Pollard et al., 2008). CD44 has
been used to enrich for putative cancer stem cells in other types
of solid cancer, such as breast, head and neck, and pancreas
and prostate (Al-Hajj et al., 2003; Patrawala et al., 2006; Li
et al., 2007; Prince et al., 2007).
To identify new candidate markers that distinguish fetal NS
cells from GNS cells, we identified the most significantly differen-
tially expressed transcripts across all six GNS cell lines versus
three fetal NS cells. Genes located on chromosome 7 were
significantly overrepresented within this set (Figure S11). This
was not unexpected, given the variable copy number increases
for this chromosome seen by SKY (Figure S2). The most signifi-
cantly downregulated gene in GNS cells relative to fetal NS cells
is the well-studied tumor suppressor PTEN, which is often lost or
mutated in gliomas and other cancers (Louis, 2006). The top 100
differentially expressed genes (excluding those on chromo-
somes 7 or 19q) provide a set of candidate markers that distin-
guish GNS cells from nontumorigenic fetal NS cells (Figure S12).
Drug Screening Using Live Imaging of Adherent
GNS Cells
The mouse neurosphere culture system has been used to screen
compounds that affect neural stem cell expansion (Diamandis
et al., 2007). However, there are several inherent limitations of
this system. First, human neural stem cells expand more slowly
in vitro than do their mouse counterparts. Quantification of cell
proliferation is required for robust screening, which is difficult
in suspension culture due to variable cell death. Second, neuro-
spheres include restricted progenitors and differentiated cell
types, and it is difficult to identify the precise cellular target.
Third, real-time monitoring of cellular responses is not possible
in aggregates. Finally, fusion of neurospheres is a common
occurrence in suspension, which confounds analyses based
solely on sphere numbers or size (Singec et al., 2006). Many of
these hurdles are overcome using adherent monolayer GNS
cells. Therefore, we undertook a proof-of-principle chemical
screen using a live-cell imaging system (IncucyteHD) to monitor
the effects of 450 compounds (NIH Clinical Collection). This
collection comprises known drugs that have passed phase I–III
trials and have been used in the clinic for various indications.
Following the addition of 10 mM of each drug, we captured live
images of six parallel 96-well plates at 30 min intervals over a
2 day period. The relative change in confluence within each576 Cell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc.individual well was measured at each time point. We carried
out two independent screens using G144, G166, and G179, as
well as a human fibroblast cell line (HS27). Thirty-eight drugs
had significant cytotoxic or cytostatic effect on at least one line
(Figures 7A–7C). Time-lapse movies of each well confirmed the
effects of these compounds. Included within this set were drugs
that disrupt core cell biological processes, including anthracy-
cline chemotherapeutics (Doxorubicin and Idarubicin), the anti-
mitotic Vindesine, and DNA topoisomerase inhibitors (Irinotecan
and Etoposide) (Figure 7C). We also found line-specific effects
for 15 compounds, consistent with the individualized pheno-
types of GNS cells (Figure 7C).
We previously reported sensitivity of mouse neurospheres to
perturbation of neurotransmitter pathways (Diamandis et al.,
2007). Intriguingly, of the 23 drugs that killed all GNS cell lines,
7 are known to modulate the monoamine-signaling pathways.
These are: two monoamine reuptake inhibitors (Indatraline and
Paroxetine), a serotonin-specific reuptake inhibitor (Sertraline),
two serotonin receptor agonists (CGS 12066B and Tegaserod),
two dopamine receptor antagonists (10H-Phenothiazine and
Trifluoperazine), and a dopamine transporter/sigma receptor
modulator (Rimcazole). A monoamine oxidase inhibitor (Trypto-
line) had a lesser but still detectable effect. Indatraline and
Paroxetine had no effect on fibroblasts. Several of the drugs
were validated using compounds obtained from an independent
supplier (Figure 7D and Movies S13–S22). Interestingly, the
addition of Indatraline, Rimcazole, or Sertraline resulted in cell
death for all tumor lines and fetal NS cells but had less or no
effect on the fibroblast cells. Following 1 hr exposure of GNS
cells to Indatraline or Sertraline, active Caspase-3 and positive
signal using the TUNEL assay were detected, confirming that
cells undergo apoptosis (Figure 7E). Taken together, these
results highlight the utility and scalability of adherent GNS cell
lines for screening purposes and extend our previous findings,
suggesting that brain cancer stem cells may be acutely sensitive
to modulation of monoamine signaling and, particularly, the
serotonin-signaling pathway.
DISCUSSION
Two critical unresolved issues relevant to the brain cancer stem
cell hypothesis are: (1) how to maintain and expand pure popu-
lations of cancer stem cells and (2) elucidation of the phenotypic
similarities between these cells and endogenous progenitors
(Stiles and Rowitch, 2008). Here, we have demonstrated that
pure populations of cancer stem cells can be expanded in vitro
as cell lines using adherent culture methods previously estab-
lished for fetal and human NS cells (Conti et al., 2005; Sun
et al., 2008). Thus, suspension culture is not a requirement for
successful long-term propagation of tumor-derived stem cells.
In fact, by expanding glioma tumor-initiating cells as adherent
cell lines, limitations of the neurosphere culture paradigm are
overcome. Furthermore, whereas neurosphere culture yields
expandable cultures from only a fraction of GBMs, our experi-
ence with adherent culture is that continuous stem cell lines
have been obtained from all specimens that start with a reason-
able cell viability. Increased levels of differentiation and
apoptosis occur when GNS cells are cultured in suspension. It
can be anticipated that sphere cultures will display a reduced
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(A) Relative cell number, derived from quantitative analyses of photomicrographs, is plotted against time for an example plate. In red are all of the ‘‘hits,’’
compounds acting within the lowest 5th percentile, reducing cell number to < 0.75. Every tenth well for all other compounds is plotted in blue to illustrate the
distribution range. Confluence readings after 2 days identify cytotoxic drugs. The Z factor for this screen was 0.76 (see Supplemental Experimental Procedures).
The dotted blue line refers to Tryptoline.
(B) Cartoon of an example 96-well plate for GNS cell line G179 and HS27 (fibroblasts). Indatraline (*) and Paroxetine (**) show differential effects that affected all
GNS cells, but not fibroblasts (HS27).
(C) Summary of active compounds. Red indicates compounds within the 5th percentile of cell confluence in two out of two screens; orange, in one of two screens;
and blue, in neither of the two.
(D) To validate the results of the screen, we applied selected compounds from an independent source (2 mM for Tegaserod, 10 mM for all others) to G179 (left), HS
27 (middle), or fetal NS (right). Live images are shown after 2 days of treatment with each compound.
(E) Exposure of G179 cells to Indatraline induces apoptosis within 1 hr, as assessed by the TUNEL assay (green) and active caspase-3 (red).tumorigenicity on a per cell basis compared to adherent GNS
cultures, although side-by-side limiting dilution transplantation
assays would be required to demonstrate this. Recently, Fael
Al-Mayhani et al. (2009) reported high efficiency of deriving
expandable glioma cultures using our adherent NS cell proto-
cols, although they provide only preliminary molecular and
phenotypic characterization.
Our findings indicate that gliomas are not driven by a single
phenotype of tumor stem cell. In adherent GNS cell culture,
tumor-specific stem cells can be distinguished based on
lineage-specific markers. Within the developing and adult
nervous system, there are several distinct classes of proliferative
progenitors (e.g., neuroepithelial cells, radial glia, glial progeni-
tors, oligodendrocyte progenitor cells, and SVZ astrocytes).
G144 cells strongly express markers of the oligodendrocyte
precursor cell/type C cell lineage and are biased toward oligo-
dendrocyte differentiation. This phenotype is stable through
passaging and is also observed in clonal cell lines. By contrast,G179 appears more similar to adult SVZ astrocytes, including
expression of GFAPd, although more specific markers will be
needed to confirm this. G166 cells are different again. Thus,
the wide and continuous histological spectrum of gliomas with
regard to proportions of the various differentiated and anaplastic
cells may be dictated by the phenotype of the underlying tumor-
initiating cells. As a larger set of GNS cell lines becomes avail-
able, we will be able to determine the frequency with which these
distinct phenotypes occur and correlate precisely with primary
tumor histopathology.
CD133 wasnot present on all GNS cell lines, confirming that this
marker does not universally identify tumorigenic cells in malignant
glioma (Beier et al., 2007). Glioblastoma-derived neurospheres
are reported to fall into two distinct groups based on their adhe-
sion properties (Gunther et al., 2007). However, markers that
specifically distinguish these two categories of culture have not
been described. Therefore, their correspondence to the GNS
cell lines cannot readily be ascertained (Figure S13).Cell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc. 577
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following transformation of OLPs or adult SVZ astrocytes.
However, it is equally plausible that short-lived progenitors or
differentiated cells can be converted to a stem cell state through
genetic/epigenetic disruptions. Indeed, OLPs in vitro can acquire
stem cell properties through sequential exposure to BMP,
PDGF, and EGF/FGF (Kondo and Raff, 2000).
GNS cells can be genetically modified, enabling sophisticated
chemical or genetic screens—for example, incorporating fluo-
rescent reporters. We have also demonstrated their utility for
morphometric analysis of cell behavior and tracking of cell
motility, an important feature of malignant gliomas (Dirks,
2001). They should also be amenable to lineage-tracing experi-
ments, as recently reported for fetal CNS progenitor cultures
(Ravin et al., 2008). Suspension culture methodology is currently
favored for propagation of cells from a range of solid tumors,
such as breast (Liao et al., 2007) and colon cancer (Ricci-Vitiani
et al., 2007). We suggest that, where possible, derivation of
adherent stem cell lines could offer significant advantages.
We demonstrated proof of principle of the utility of GNS cells
by carrying out a small-scale chemical screen of known pharma-
ceutical drugs. The findings extend to human brain cancer stem
cells our observation that mouse neurospheres are sensitive to
modulation of neurotransmitter pathways (Diamandis et al.,
2007). Future studies will determine whether those drugs that
modulate the serotonin pathway can limit growth of xenograft
tumors in vivo.
In conclusion, GNS cells provide a versatile and renewable
resource to probe the biology of tumor-initiating cells and screen
for agents that selectively and directly target them. Tumor stem
cell self-renewal, migration, apoptosis, and differentiation all
represent potential therapeutic opportunities that are accessible
in GNS cell cultures.
EXPERIMENTAL PROCEDURES
Tumor Samples and Cell Culture
Brain tumor samples were obtained following local ethical board approval.
G144 and G144ED (51-year-old male), G166 (74-year-old female), and GliNS2
(54-year-old male) were diagnosed as classic glioblastoma multiform (GBM).
G179 (56-year-old male) was a GBM (giant cell variant). G174 (60-year-old
male) was an anaplastic oligodendroglioma. Tumors were dissociated into
single cells by placing in Accutase (Sigma) or an enzyme cocktail for 15–20
min at 37C (Singh et al., 2003). For those tumors with excess debris, cells
were initially allowed to form spheres/aggregates in suspension culture, and
these were then transferred to a fresh laminin-coated flask. They subsequently
attached and began to outgrow over the course of a week.
Culture of GNS Cells
GNS cell expansion was carried out using serum-free media supplemented
with N2, B27, EGF, and FGF-2 (20 ng/ml), as described previously for human
fetal NS cells (Sun et al., 2008). Culture vessels were coated with Laminin
(Sigma) for 3 hr at 10 ug/ml prior to use. GNS cells were routinely grown to
confluence, dissociated using Accutase (Sigma), and then split 1:3 to 1:5.
Medium was replaced every 3–5 days. Foetal NS cells CB541 and CB660
have been described previously (Sun et al., 2008), and hf240, hf286, and
hf289 were isolated using similar techniques (I.C., unpublished data). GNS
cell lines have been deposited in the ATTC and can be requested from the
cell repository at Biorep (Milan, Italy). For differentiations, we used laminin-
coated 4-well plates (0.5 1 3 105 cells/well) (Nunc) or 24-well Imagelock
microplates (Essen Instruments). For oligodendrocytes and neuronal differen-
tiation, we used the same basal media but lacking EGF or FGF-2 (i.e., growth578 Cell Stem Cell 4, 568–580, June 5, 2009 ª2009 Elsevier Inc.factor withdrawal). For astrocyte differentiation, we added BMP at 10 ng/ml
(R and D Systems). A detailed protocol is available in the Supplemental Exper-
imental Procedures.
Genomic Analysis
Cultures were colcemid treated for cytogenetic harvest. Spectral Karyotyping
(SKY) was performed using the commercially available kit provided by Applied
Spectral Imaging (Vista, CA). Slides were imaged and analyzed by fluorescent
microscope. For CGH analysis, 1.5 ug genomic DNA was prepared using
Wizard genomic DNA extraction kit (Promega). Sample preparation, CGH
hybridization, and analysis were performed using human 43 44 k CGH micro-
arrays, feature extraction, and CGH analytics software (Agilent). Significant
chromosomal aberrations have been determined using algorithm ADM-2
(window = 5 kb; threshold = 15.5).
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) was performed on cytogenetic
preparations or formalin-fixed paraffin-embedded (FFPE) sections using the
Centromere 7-specific and EGFR-locus-specific FISH probes provided by
Vysis (Abbott Technologies).
Immunocytochemistry
Immunocytochemistry was performed as described previously (Conti et al.,
2005). Primary antibodies: human Nestin (1:500), O4 (1:100, live stain), and
Sox2 (1:50) (R and D Systems); Vimentin (1:50), 3CB2 (1:20) (DSHB, University
of Iowa), and TuJ-1 (1:500) (Covance); CD44 (1:100, live stain) (E-bioscience);
GFAP (1:300) (Sigma, monoclonal GA-5); and NG2 (1:100), Olig2 (1:200), and
GFAPd (1:200) (Chemicon). We used goat secondary antibodies conjugated
to Alexa dyes, 1:1000 (Molecular Probes). For analysis of apoptosis, we
treated cells with either DMSO (0.1%) or Indatraline 10 uM or Sertraline
10 uM. After 1 hr treatment, cells were fixed for 30 min with 4% PFA and
were permeabilized with Triton X-100 and sodium citrate 0.1%. Cells were
then assessed using the TUNEL assay (In Situ Cell Death Detection kit, Roche)
and subsequently processed for immunocytochemistry using an anti active
Caspase-3 antibody (BD PharMingen). DAPI was used as nuclear counterstain
(Sigma). Images were acquired using a Leica DMI400B inverted fluorescence
microscope linked to a DFC340FX camera.
Flow Cytometry
We used the following antibodies: CD133 (1:5) (Miltenyi), CD15 (1:100) (BD),
and CD44-PE/Cy5 (1:1000) (eBioscience). Clonal cell lines were established
using a flow sorter (MoFlo, Dako) to deposit single cells into each well of
a 96-well plate.
Mouse Brain Fixation, Histopathology, and Immunohistochemistry
These procedures were carried out as described (Singh et al., 2004). Antibody
staining was carried out following deparaffinisation and heat-induced antigen
retrieval using citrate buffer (pH 6.0). The antibodies used were CNPase 1:200
(Sigma), hNestin 1:200 (Millipore), hGFAP 1:200 (Sternberger monoclonals),
and GFAP-d, 1:500 (Millipore).
Xenotransplantation
GNS cells were injected stereotactically into 6- to 8-week-old NOD-SCID
mouse frontal cortex, following administration of general anesthesia. Details
are available in the Supplemental Experimental Procedures.
Microarrays and Bioinformatics
Expression profiling was carried out using the GeneChip Human Genome
U133 Plus 2.0 Array (Affymetrix). Data were preprocessed using Bioconductor
packages: affyQCReport for quality control checks and the vsnrma function of
the Bioconductor package vsn for data normalization. The limma package in
Bioconductor was used for statistically analyzing the data using both the modi-
fied t test and f test and the false discovery rate (FDR) method for multiple
hypothesis correction. Dendograms and heatmap plots were created using
the hclust package in Bioconductor. Hierarchical clustering (using the
Euclidean distance and the average linkage method) was performed on the
normalized data set and then on various lists of statistically significant differen-
tially expressed genes. Umetrics software was used to perform a principal
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Glioma NS Cell Linescomponents analysis (PCA) on the normalized data set, and partial least
square discriminant analysis (PLS-DA) was used to determine group classi-
fiers. The Web-based tool GeneTrail (http://genetrail.bioinf.uni-sb.de/) was
used to perform both overrepresentation analysis and gene set enrichment
analysis. Array data are available from the NIH Gene Expression Omnibus
(accession number GSE15209).
Quantitative RT-PCR
Total mRNA was harvested using the QIAGEN RNeasy kit (QIAGEN). cDNA
was generated using Superscript III (Invitrogen), and quantitative PCR was
carried out using the LightCycler system (Roche). Data presented here are
means of biological and technical duplicates. Samples were normalized using
b-actin primers, and the data are expressed relative to fetal NS cell (CB660)
expression. Primers were designed using Primer 3 software (MIT): GFAPdF
ACATCGAGATCGCCACCTAC; GFAPdR, CGGCGTTCCATTTACAATCT; GF
APaF, ACATCGAGATCGCCACCTAC; GFAPaR, ATCTCCACGGTCTTCAC
CAC; PDGFRaF, CCACCGTCAAAGGAAAGAAG; PDGFRaR, CCAATTTGAT
GGATGGGACT; PDGFAF, GATACCTCGCCCATGTTCTG; PDGFAR, CAGG
CTGGTGTCCAAAGAAT; Olig2F, CAGAAGCGCTGATGG; and Olig2R, TCG
GCAGTTTTGGGT.
Immunoblotting
A 10% protein gel (Invitrogen) was used, and blotting was performed using the
iBlot Dry Blotting system (Invitrogen). Antibodies were anti-a-tubulin antibody
at 1:5000 (Abcam), anti-GFAPd 1:500 (Chemicon), and GFAP 1:500 (Sigma).
Secondary antibody conjugated to HRP was used with the ECL system to
detect protein (Amersham).
Time-Lapse Movies and Drug Screening
For routine time-lapse imaging and generation of growth curves, we used the
Incucyte system (Essen Instruments, USA). For cell tracking analysis, we pro-
cessed image stacks using ImageJ and analyzed cell tracks using the MTrackJ
Plugin (http://rsb.info.nih.gov/ij/).
We used the NIH clinical collection of 480 compounds (www.
nihclinicalcollection.com). The IncucyteHD system (Essen Instruments, USA)
enables simultaneous monitoring of six 96-well microplates. GNS cell lines
were plated at 10%–20% confluence on 96-well plates (Iwaki). Compounds
were added to the plates at a final concentration of 10 mM per compound
per well (DMSO 0.1%). Relative increase in cell number values was generated
for every well using confluence readings obtained at each time point relative to
the starting confluence. For every cell line (G144, G166, G179, and HS27), two
independent screens were run. HS27 is a human foreskin fibroblast line (Amer-
ican Type Culture Collection). Every well associated with a reduction in cell
number within the 5th percentile in at least two independent screens was visu-
ally inspected. For validation, a few chosen compounds were received from an
independent supplier—Indatraline, Rimcazole, and Sertraline (Sigma) and
Tegaserod (Sequoia Research Products)—and a similar set of experiments
was conducted in 24 wells with 2 mM or 10 mM of compound.
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sion Omnibus with accession number GSE15209.
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